Cargando…

Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities

Psoriasis is a common chronic immune-mediated inflammatory skin disorder and begins in childhood in almost one-third of the cases. Although children present with the same clinical subtypes of psoriasis seen in adults, lesions may differ in distribution and morphology, and their clinical symptoms at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bronckers, I. M. G. J., Paller, A. S., van Geel, M. J., van de Kerkhof, P. C. M., Seyger, M. M. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744260/ https://www.ncbi.nlm.nih.gov/pubmed/26072040 http://dx.doi.org/10.1007/s40272-015-0137-1

Ejemplares similares

Treatment persistence in paediatric and adolescent patients with psoriasis followed into young adulthood. From topical to systemic treatment: a prospective, longitudinal, observational cohort study of 448 patients
por: Bruins, F.M., et al.
Publicado: (2020)

Real-world Methotrexate Use in a Prospective Cohort of Paediatric Patients with Plaque Psoriasis: Effectiveness, Adverse Events and Folic Acid Regimen
por: BRUINS, Finola M., et al.
Publicado: (2022)

Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
por: Seyger, M.M.B., et al.
Publicado: (2021)

Image‐based automated Psoriasis Area Severity Index scoring by Convolutional Neural Networks
por: Schaap, M.J., et al.
Publicado: (2021)

Patient-reported Outcomes and Burden of Disease in Paediatric Patients with Psoriasis: Real-world Data from EU5 and US
por: SEYGER, Marieke M. B., et al.
Publicado: (2023)

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Jackson, Kimberley, et al.
Publicado: (2021)

A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population
por: Paller, Amy S., et al.
Publicado: (2019)

The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review
por: van Acht, Maartje R, et al.
Publicado: (2022)

Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
por: Mahé, E., et al.
Publicado: (2022)

Patients’ perspectives towards biologic dose reduction in psoriasis: a qualitative study
por: van der Schoot, L. S., et al.
Publicado: (2023)

Psoriasis and Atopic Dermatitis
por: Griffiths, Christopher E. M., et al.
Publicado: (2017)

Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study
por: SEYGER, Marieke M. B., et al.
Publicado: (2022)

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey
por: van de Kerkhof, P.C.M., et al.
Publicado: (2015)

Perfusion measured by laser speckle contrast imaging as a predictor for expansion of psoriasis lesions
por: Schaap, Mirjam J., et al.
Publicado: (2021)

Psoriasis: Comorbidities
por: Yamazaki, Fumikazu
Publicado: (2021)

Safety and efficacy of fixed‐dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open‐label trial
por: Seyger, M., et al.
Publicado: (2020)

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2022)

Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis
por: Langewouters, A. M. G., et al.
Publicado: (2007)

Diagnosis and underdiagnosis of comorbidities in psoriasis patients - need for a multidisciplinary approach
por: Duarte, Gleison Vieira, et al.
Publicado: (2016)

Psoriasis: classical and emerging comorbidities()
por: de Oliveira, Maria de Fátima Santos Paim, et al.
Publicado: (2015)

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Paller, A.S., et al.
Publicado: (2020)

Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management
por: De Brandt, Eveline, et al.
Publicado: (2022)

Psoriasis: new comorbidities
por: Machado-Pinto, Jackson, et al.
Publicado: (2016)

Comorbidity in Men with Psoriasis
por: Salihbegovic, Eldina Malkic, et al.
Publicado: (2021)

Management of psoriasis in adolescence
por: Fotiadou, Christina, et al.
Publicado: (2014)

Handheld versus mounted laser speckle contrast perfusion imaging demonstrated in psoriasis lesions
por: Chizari, Ata, et al.
Publicado: (2021)

Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2015)

Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis
por: Valenzuela, Fernando, et al.
Publicado: (2022)

Challenges in Noninvasive Skin Biomarker Measurements in Daily Practice: A Longitudinal Study on Skin Surface Protein Detection by the Transdermal Analysis Patch in Pediatric Psoriasis
por: Schaap, Mirjam J., et al.
Publicado: (2022)

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
por: van der Schoot, L.S., et al.
Publicado: (2023)

A European subset analysis from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country‐specific features: results from psoriasis patients in Spain
por: Puig, L., et al.
Publicado: (2017)

Psoriasis comorbidity management in the COVID era: a pressing challenge
por: Song, Yang, et al.
Publicado: (2023)

Psoriasis and comorbidities: links and risks
por: Ni, Catherine, et al.
Publicado: (2014)

Metabolic comorbidities of psoriasis (Review)
por: Branisteanu, Daciana Elena, et al.
Publicado: (2022)

Cardiovascular comorbidities in psoriasis (Review)
por: Branisteanu, Daciana Elena, et al.
Publicado: (2022)

Immunity: Psoriasis comorbid with atherosclerosis
por: Liu, Chunping, et al.
Publicado: (2022)

Highlights of the updated Dutch evidence‐ and consensus‐based guideline on psoriasis 2017
por: van der Kraaij, G.E., et al.
Publicado: (2019)

Safety of treatment with biologics for psoriasis in daily practice: 5-year data
por: Van Lümig, PPM, et al.
Publicado: (2010)

Enhanced screening for posttraumatic stress disorder and comorbid diagnoses in children and adolescents
por: Verlinden, Eva, et al.
Publicado: (2015)

Disease and Treatment Characteristics in Geriatric Psoriasis: A Patient Survey Comparing Age Groups
por: VAN WINDEN, Marieke E. C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hijp2vglrtg8info8q75dr4bg1